McGill University Health Centre

Montréal, QC

Sorting 2 by

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

AZD0305

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Learn more
  • Antibody Drug Conjugate (ADC)
  • GPRC5D
  • Phase 1/2